Bjorn Tackenberg

Marburg An Der Lahn, HE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 88 publications

Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis.

Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis.

Journal: JAMA neurology

Published: August 03, 2026

Genetic Risk Variants for Multiple Sclerosis and Other Loci Linked to Intrathecal Immunoglobulin G Synthesis.

Genetic Risk Variants for Multiple Sclerosis and Other Loci Linked to Intrathecal Immunoglobulin G Synthesis.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: October 15, 2025

Speech as a digital biomarker in multiple sclerosis: Automatic analysis of speech metrics using a multi-speech-task protocol in a cross-sectional MS cohort study.

Speech as a digital biomarker in multiple sclerosis: Automatic analysis of speech metrics using a multi-speech-task protocol in a cross-sectional MS cohort study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: June 14, 2025

GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.

GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.

Journal: Brain : a journal of neurology

Published: June 14, 2025

GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.

GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.

Journal: Brain : a journal of neurology

Published: June 14, 2025

Federated learning for lesion segmentation in multiple sclerosis: a real-world multi-center feasibility study.

Federated learning for lesion segmentation in multiple sclerosis: a real-world multi-center feasibility study.

Journal: Frontiers in neurology

Published: May 27, 2025

Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS.

Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: April 16, 2025

B- and T cell receptor sequencing elucidates characteristics of lymphocyte depletion by ocrelizumab.

B- and T cell receptor sequencing elucidates characteristics of lymphocyte depletion by ocrelizumab.

Journal: iScience

Published: April 04, 2025

Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response.

Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response.

Journal: Annals of clinical and translational neurology

Published: April 01, 2025

Quality of Life in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.

Quality of Life in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.

Journal: Muscle & nerve

Published: March 21, 2025

Detecting fatigue in multiple sclerosis through automatic speech analysis.

Detecting fatigue in multiple sclerosis through automatic speech analysis.

Journal: Frontiers in human neuroscience

Published: June 14, 2024

Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis.

Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis.

Journal: Annals of neurology

Published: May 24, 2024

Showing 1-12 of 88

Last Updated: 09/26/2026